CONSOLIDATED STATEMENTS OF CHANGES IN EQUITY - USD ($) $ in Millions		Total	Adjustment	Preferred Stock	Common Stock	Capital Surplus	Retained Earnings	Retained Earnings Adjustment	Accumulated Other Comprehensive Income (Loss)		Noncontrolling Interest
Preferred stock, balance, beginning of period (in shares) at Dec. 31, 2023				26,750
Common stock, balance, beginning of period (in shares) at Dec. 31, 2023					558,838,694
Balance, beginning of period at Dec. 31, 2023		$ 9,291	$ 8	$ 520	$ 349	$ 5,351	$ 3,964	$ 8	$ (1,188)	[1]	$ 295
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net income		197					192				5
Other comprehensive income (loss)		(83)							(83)	[1]
Cash dividends declared:
Preferred stock		(8)					(8)
Common stock		(84)					(84)
Common stock repurchased (in shares)	[2]				(11,051,980)
Common stock repurchased	[2]	(159)			$ (7)	(152)
Excise tax on common stock repurchased		(2)				(2)
Common stock issued for:
Stock options exercised and restricted stock awards (in shares)					850,272
Stock options exercised and restricted stock awards		0
Stock-based compensation expense		18			$ 1	17
Dividends declared - noncontrolling interest of subsidiary preferred stock		(5)									(5)
Preferred stock, balance, ending of period (in shares) at Mar. 31, 2024				26,750
Common stock, balance, ending of period (in shares) at Mar. 31, 2024					548,636,986
Balance, ending of period at Mar. 31, 2024		9,173		$ 520	$ 343	5,214	4,072		(1,271)	[1]	295
Preferred stock, balance, beginning of period (in shares) at Dec. 31, 2023				26,750
Common stock, balance, beginning of period (in shares) at Dec. 31, 2023					558,838,694
Balance, beginning of period at Dec. 31, 2023		9,291	$ 8	$ 520	$ 349	5,351	3,964	$ 8	(1,188)	[1]	295
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net income		401
Other comprehensive income (loss)		(93)							(93)
Preferred stock, balance, ending of period (in shares) at Jun. 30, 2024				16,750
Common stock, balance, ending of period (in shares) at Jun. 30, 2024					536,875,750
Balance, ending of period at Jun. 30, 2024		8,955		$ 426	$ 336	5,007	4,172		(1,281)	[1]	295
Preferred stock, balance, beginning of period (in shares) at Mar. 31, 2024				26,750
Common stock, balance, beginning of period (in shares) at Mar. 31, 2024					548,636,986
Balance, beginning of period at Mar. 31, 2024		9,173		$ 520	$ 343	5,214	4,072		(1,271)	[1]	295
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net income		204					199				5
Other comprehensive income (loss)		(10)							(10)	[1]
Cash dividends declared:
Preferred stock		(8)					(8)
Common stock		(84)					(84)
Series D preferred stock redemption (in shares)				(10,000)
Series D preferred stock redemption		(100)		$ (94)			(6)
Excise tax on preferred stock redemption		(1)					(1)
Common stock repurchased (in shares)	[2]				(14,896,091)
Common stock repurchased	[2]	(228)			$ (9)	(219)
Excise tax on common stock repurchased		(1)				(1)
Common stock issued for:
Stock options exercised and restricted stock awards (in shares)					3,134,855
Stock options exercised and restricted stock awards		2			$ 1	1
Stock-based compensation expense		13			$ 1	12
Dividends declared - noncontrolling interest of subsidiary preferred stock		(5)									(5)
Preferred stock, balance, ending of period (in shares) at Jun. 30, 2024				16,750
Common stock, balance, ending of period (in shares) at Jun. 30, 2024					536,875,750
Balance, ending of period at Jun. 30, 2024		8,955		$ 426	$ 336	5,007	4,172		(1,281)	[1]	295
Preferred stock, balance, beginning of period (in shares) at Dec. 31, 2024				16,750
Common stock, balance, beginning of period (in shares) at Dec. 31, 2024					524,280,412
Balance, beginning of period at Dec. 31, 2024		9,111		$ 426	$ 328	4,808	4,382		(1,128)	[3]	295
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net income		222					218				4
Other comprehensive income (loss)		145							145	[3]
Cash dividends declared:
Preferred stock		(5)					(5)
Common stock		(78)					(78)
Common stock repurchased (in shares)	[4]				(17,657,334)
Common stock repurchased	[4]	(365)			$ (11)	(354)
Excise tax on common stock repurchased		(3)				(3)
Common stock issued for:
Stock options exercised and restricted stock awards (in shares)					692,106
Stock options exercised and restricted stock awards		3				3
Stock-based compensation expense		18				18
Dividends declared - noncontrolling interest of subsidiary preferred stock		(4)									(4)
Preferred stock, balance, ending of period (in shares) at Mar. 31, 2025				16,750
Common stock, balance, ending of period (in shares) at Mar. 31, 2025					507,315,184
Balance, ending of period at Mar. 31, 2025		9,044		$ 426	$ 317	4,472	4,517		(983)	[3]	295
Preferred stock, balance, beginning of period (in shares) at Dec. 31, 2024				16,750
Common stock, balance, beginning of period (in shares) at Dec. 31, 2024					524,280,412
Balance, beginning of period at Dec. 31, 2024		9,111		$ 426	$ 328	4,808	4,382		(1,128)	[3]	295
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net income		467
Other comprehensive income (loss)		$ 216							216
Preferred stock, balance, ending of period (in shares) at Jun. 30, 2025		16,750		16,750
Common stock, balance, ending of period (in shares) at Jun. 30, 2025					508,835,780
Balance, ending of period at Jun. 30, 2025		$ 9,257		$ 426	$ 318	4,459	4,671		(912)	[3]	295
Preferred stock, balance, beginning of period (in shares) at Mar. 31, 2025				16,750
Common stock, balance, beginning of period (in shares) at Mar. 31, 2025					507,315,184
Balance, beginning of period at Mar. 31, 2025		9,044		$ 426	$ 317	4,472	4,517		(983)	[3]	295
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net income		245					241				4
Other comprehensive income (loss)		71							71	[3]
Cash dividends declared:
Preferred stock		(8)					(8)
Common stock		(79)					(79)
Common stock repurchased (in shares)	[4]				(1,455,166)
Common stock repurchased	[4]	(27)			$ (1)	(26)
Common stock issued for:
Stock options exercised and restricted stock awards (in shares)					2,975,762
Stock options exercised and restricted stock awards		0
Stock-based compensation expense		15			$ 2	13
Dividends declared - noncontrolling interest of subsidiary preferred stock		$ (4)									(4)
Preferred stock, balance, ending of period (in shares) at Jun. 30, 2025		16,750		16,750
Common stock, balance, ending of period (in shares) at Jun. 30, 2025					508,835,780
Balance, ending of period at Jun. 30, 2025		$ 9,257		$ 426	$ 318	$ 4,459	$ 4,671		$ (912)	[3]	$ 295

[1] Due to the nature of the preferred stock issued by FHN and its subsidiaries, all components of other comprehensive income (loss) have been attributed solely to FHN as the controlling interest holder.

[2] Includes $154 million and $212 million repurchased during first and second quarter, respectively, under FHN's $650 million general purchase program approved in January 2024 and terminated in October 2024.

[3] Due to the nature of the preferred stock issued by FHN and its subsidiaries, all components of other comprehensive income (loss) have been attributed solely to FHN as the controlling interest holder.

[4] Includes $360 million and $9 million repurchased during first and second quarter, respectively, under FHN's $1 billion general purchase program approved in October 2024 and scheduled to expire in January 2026.